A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects-Reference-Cited by-同舟云学术

A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects

Published:2017-03-01 Issue:3 Volume:42 Page:268-275
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Krauwinkel W.¹,Noukens J.²,van Dijk J.¹,Popa S.³,Ouatas T.¹,de Vries M.¹,Phung D.¹,Gibbons J.⁴,Mordenti J.⁴,Mateva L.⁵

Affiliation:

1. Astellas Pharma Europe; Leiden The Netherlands

2. Kinesis Pharma BV; Breda The Netherlands

3. ARENSIA Exploratory Medicine; Republican Clinical Hospital; Chisinau Moldova

4. Medivation, Inc., (Medivation was acquired by Pfizer, Inc. in September 2016); San Francisco CA USA

5. Gastroenterology Clinic; University Hospital St. Ivan Rilski; Medical University Sofia; COMAC Medical Ltd; Sofia Bulgaria

Funder

Astellas Pharma US

Medivation, Inc.

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcpt.12503/fullpdf

Reference17 articles.

1. Development of a second-generation antiandrogen for treatment of advanced prostate cancer;Tran;Science,2009

2. Astellas Pharma US, Inc., Medivation, Inc XTANDI US Prescribing Information http://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf?v=1

3. Astellas Pharma US, Inc., Medivation, Inc. Xtandi Summary of Product Characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002639/WC500144996.pdf

4. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

5. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact;Expert Opinion on Drug Metabolism & Toxicology;2024-05-22

2. Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay;Clinical Pharmacology & Therapeutics;2024-02-26

3. Cocrystal and Coamorphous Solid Forms of Enzalutamide with Saccharin: Structural Characterization and Dissolution Studies;Crystal Growth & Design;2022-10-08

4. AR independent anticancer potential of enza against prostate cancer;Colloids and Surfaces A: Physicochemical and Engineering Aspects;2022-06

5. Antiandrogen enzalutamide induced genetic, cellular, and hepatic damages: amelioration by triterpene Lupeol;Drug and Chemical Toxicology;2022-02-21